

Combinación de inmunoterapia en primera línea de enfermedad avanzada

Dra. Noemí Reguart
Hospital Universitario Clínic de Barcelona

Iniciativa científica de:



Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group


Con el patrocinio de



Tumor Mutational Burden (TMB) as a Biomarker for Clinical Benefit From Dual Immune Checkpoint Blockade With Nivolumab + Ipilimumab in First-line Non-Small Cell Lung Cancer: Identification of TMB Cutoff From CheckMate 568

Suresh S. Ramalingam,¹ Matthew D. Hellmann,² Mark M. Awad,³ Hossein Borghaei,⁴ Justin Gainor,⁵ Julie Brahmer,⁶ David R. Spigel,⁷ Martin Reck,⁸ Kenneth J. O'Byrne,⁹ Luis Paz-Ares,¹⁰ Kim Zerba,¹¹ Xuemei Li,¹¹ William J. Geese,¹¹ George Green,¹¹ Brian Lestini,¹¹ Joseph D. Szustakowski,¹¹ Han Chang,¹¹ Neal Ready¹²



¹Winship Cancer Institute, Emory University, Atlanta, GA, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Dana-Farber Cancer Institute, Boston, MA, USA; ⁴Fox Chase Cancer Center, Philadelphia, PA, USA; ⁵Massachusetts General Hospital, Boston, MA, USA; ⁶Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; ⁷Sarah Cannon Research Institute, Nashville, TN, USA; ⁸Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; ⁹Princess Alexandra Hospital, Brisbane, Queensland, Australia; ¹⁰Hospital Universitario Doce de Octubre, CNIO, Universidad Complutense & CiberOnc, Madrid, Spain; ¹¹Bristol-Myers Squibb, Princeton, NJ, USA; ¹²Duke University Medical Center, Durham, NC, USA



Database lock: August 24, 2017; minimum follow-up: 6 months; median follow-up: 8.8 months

^aNCT02659059; ^bEfficacy analyses by blinded independent central review (BICR); ^cPD-L1 status determined by Dako PD-L1 IHC 28-8 pharmDx immunohistochemical test

CheckMate 568 Summary: Nivolumab + Ipilimumab in 1L NSCLC



culated by whole exome sequencing and values were converted to mutations/Mb

CheckMate 568 Summary: Nivolumab + Ipilimumab in 1L NSCLC

ORR by TMB^{a,b}

